
News|Videos|August 1, 2024
Emerging Treatments in Mild/Moderate Multiple Sclerosis
Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).
Advertisement
Episodes in this series

BTK inhibitors: Do the current data suggest this strategy for mild MS?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Key Neurology Trial Readouts to Watch in Early 2026
2
BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies
3
Inside the 2026 MDA Conference: Emerging Research Themes in Neuromuscular Medicine
4
Neuroprotective Agent Privosegtor Gains FDA Breakthrough Designation for Optic Neuritis
5























